Results: Mean age was 64 +/-11.2 years, 84.4% males, 30.2% diabetics and 59.6% had unstable angina at inclusion. 54.3% with 3 vessels and ULM, 1.8 +/-0.3 Firebird-2 per pt was implanted. Clinical success was accomplished in 100%. At discharge all pts received DAPT. Complete 6 months follow-up results are reported in Table. In pts with diabetes, Firebird-2 group also showed a benefit in MACCE compared to ERACI 3-DES p¼0.02 and ERACI 3-CABG p¼0.04.
Background: The ION Registry assessed clinical outcomes for the thin-strut, IONÔ (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Coronary Stent System (Boston Scientific, Natick, MA) in unselected patients at 40 sites in the United States. Two-year "real world" results with this stent have not been previously reported.
Methods:
This prospective, open-label registry enrolled 1120 consenting allcomer patients treated with the ION stent for any indication at each site. Followup was at discharge, 30 and 180 days, and annually to 5 years. The primary endpoint was the 1-year rate of cardiac death or MI in PERSEUS-like patients (ie, patients who met the enrollment criteria for the pivotal PERSEUS trial; JACC 2010;56:264-71). Per protocol, the primary endpoint result from the ION registry was also combined with the EU post-approval registry (TE-PROVE), which enrolled 306 PERSEUS-like patients, and the PERSEUS WH/SV populations (N¼1166). Results: Among 1111 patients who received a study stent, most (70.3%, 781/ 1111) were male, with a mean age of 64.1AE11.0 years, and 316 were PERSEUSlike. At 1-year, clinical follow-up or death were recorded in 92.1% (1023/1111). The primary endpoint of cardiac death or MI at 1 year occurred in 2.1% (6/292) of PERSEUS-like patients in ION and 2.3% (40/1729) patients in the combined analysis. The upper 1-sided 95% CI for the combined analysis was 2.9%, which was significantly less than the prespecified performance goal of 7.6% (P< 0.001). Additional 1-year clinical endpoint rates were 9.4% (97/1028) MACE (defined as cardiac death, MI, TVR), 2.0% (21/1028) cardiac death (0.4% related to ION stent), 3.0% (31/1028) MI (1.9% related to ION stent), 6.8% (70/1028) TVR (4.9% related to ION stent), and 2.1% (22/1028) ARC definite/probable ST (2.0% related to ION stent). Conclusions: The 1-year results of the ION US Post-Approval Study confirm the safety and effectiveness of the ION stent for the treatment of coronary artery disease in everyday clinical practice. Two-year overall results and results from selected subsets of this real-world population (diabetes, small vessels, long lesions) will be available for the first time at TCT 2014. Background: It remains unclear whether there are differences in the safety and efficacy outcomes between Cobalt Chronium (CoCr-EES) and Platinum Chronium everolimus-eluting stents (PtCr-EES). Methods: From the Interventional Cardiology Research In-Cooperation SocietyDrug-Eluting Stents Registry, we identified 6065 consecutive patients who received CoCr-EES (3080 patients) and PtCr-EES (2985 patients). We compared major adverse cardiac events (MACE) which was defined using a composite measure consisting of death, nonfatal myocardial infarction, or target vessel revascularization (TVR) with the use of propensity-score matching in the overall cohort according to type of stents. Results: At 2-years of clinical follow-up, the 2 study groups (2510 patients for each propensity-score matched group) did not differ significantly in crude risk of the MACE (12.0% for CoCr-EES versus 11.6% for PtCr-EES; HR, 0.954; 95% CI, 0.81 -1.13, p¼0.581). There was also no differences between the stent groups in the risks of the individual component of death (HR, 1.083; 95% CI, 0.786 -1.492, p¼0.624), MI (HR, 0.972; 95% CI, 0.770 -1.228, p¼0.812), and TVR (HR, 0.798; 95% CI, 0.598 -1.065, p¼0.125). The risk of cerebrovascular event (HR, 0.914; 95% CI, 0.566 -1.477, p¼0.714) and definite stent thrombosis (HR, 1.000; 95% CI, 0.290 -3.454, p¼1.000) were also similar between the two groups.
Conclusions: The use of CoCr-EES and PtCr-EES showed similar rates of safety and efficacy outcomes with regard to death, MI, stent thrombosis and TVR. Background: The TE-PROVE post-market registry has enrolled 1014 patients at 37 sites in the EU to evaluate real-world clinical outcomes for patients receiving the paclitaxel-eluting, platinum chromium TAXUS ElementÔ stent (Boston Scientific, Natick, MA). This is the first report of 2-year outcomes with the TAXUS Element stent in everyday clinical practice. Methods: The primary endpoint of overall and study stent-related target vessel failure (TVF, defined as cardiac death, and target vessel-related MI and reintervention [TVR] ) at 1 year post-implantation was 6.0% (59/987), of which 3.7% (37/9874) was considered related to the study stent (Tamburino et al, TCT 2013) . Follow-up in TE-PROVE will continue annually through 5 years. Secondary endpoints included the components of TVF, all-cause mortality, and ARC definite/probable stent thrombosis. An independent Clinical Events Committee adjudicated all events for relatedness to the study stent. Conclusions: In this robust real world registry with unrestricted use of EES and ZES-R, both stents showed comparable safety and efficacy at 3-year follow-up. Overall incidences of target lesion failure and definite stent thrombosis, including very late stent thrombosis, were low, even in the patients with off label indications, suggesting excellent long term safety and sustained efficacy of both types of second generation DES.
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Percutaneous Background: There is still uncertainty about the durability of the results of drugeluting stents (DES) in real-world complex patients. We sought to provide the longest clinical follow-up data on outcomes of unselected patients treated solely with DES. Methods: The DESIRE registry is a prospective, single-center registry encompassing all consecutive patients treated solely with DES since May 2002. The primary goal is the very long-term occurrence of MACE and stent thrombosis (ST). Patients were clinically followed at 1, 6 and 12 months and then annually. A multivariate model was built to determine independent predictors of MACE, TLR and ST. Results: A total of 5,500 patients were included. The mean age was 64 AE 11 years. DM was detected in 29.7% and 44.8% presented with acute coronary syndrome. SVG lesions and STEMI represented 6% and 12% of the cohort, respectively. Follow-up was obtained in 98.2% of the patients (median 5.6 years). Currently, 79.6% of the population is free of any MACE. TVR was performed in 5.3% of the patients. Q-wave MI rate was only 1.7% while total ST rate was 1.9%. The majority of definite ST cases occurred between the 1st and 3rd years. Independent predictors of MACE were treatment of SVG (HR 1,63; 95% CI, 1.22 to 2.18, p¼ 0.001), multivessel disease (HR 1.39; 95% CI, 1.03 to 1.87, p< 0.001), residual stenosis (HR 1.3; 95% CI, 1.1 to 1.5, p¼ 0.034), DM (HR 1.6; 95% CI, 1.1 to 2.2, p¼ 0.006) and renal insufficiency (HR 1.5; 95% CI, 1.34 to 1.81, p¼ 0.004). Independent predictors of ST were PCI for STEMI (HR 3.5; 95% CI, 1.3 to 9.4, p¼ 0.013), stent length (HR 1.8; 95% CI, 1.09 to 3.02, p¼0.023), moderate/severe calcification at lesion site (HR 2.38; 95% CI, 1.34 to 4.23, p¼0.003), and in-stent residual stenosis (HR 1.04; 95% CI, 1.01 to 1.06, p¼0.003). Conclusions: In our single center experience, the use of DES was associated with very long-term safety and effectiveness with acceptable low rates of adverse clinical events, including ST. 
